Novel research model discovered for auto-immune disease studyLaboratory Products NewsAntibodies are proteins used by the immune system to identify and neutralize foreign objects (antigens), such as bacteria and viruses, by precisely binding to them, th…
Biomarker promising for predicting HPV-related oropharynx cancerOncology Nurse AdvisorAntibodies against the human papillomavirus (HPV) may help identify those with a greatly increased risk for HPV-related cancer of the oropharynx, which is a portion o…
|
BioInvent extends license agreement with Mitsubishi Tanabe for development of …
pharmabiz.com BioInvent International AB, a research-based pharmaceutical company, has extended its 2009 license agreement with Mitsubishi Tanabe Pharma Corporation for the development of antibodies from BioInvent’s n-CoDeR library. Under the terms of the … |
Rituximab plus chlorambucil extend event-free survival in MALT lymphomaThe Oncology ReportPatients who have mucosa-associated lymphoid tissue lymphoma and are treated with chlorambucil plus rituximab have better event-free survival and progression-free…
|
Biogen Idec Given “Neutral” Rating at Piper Jaffray (BIIB)
Mideast Time … in particular unpublished estimates) now fully reflect Tecfidera’s strong launch, in our view, and upside in BIIB shares will likely require pipeline success, which is not expected until 2014 data readouts from anti-LINGO Phase II (optic neuritis … |
|
Daclizumab (Multiple Sclerosis) – Forecast and Market Analysis to 2022: New …
SBWire (press release) Boston, MA — (SBWIRE) — 07/03/2013 — GlobalData has released its new PharmaPoint Drug Evaluation report, “Daclizumab (Multiple Sclerosis) – Forecast and Market Analysis to 2022″. Multiple sclerosis (MS) is a chronic, inflammatory neurological … |
|
In the fight against cancer, do Quebeckers stand the same chance?
Canada NewsWire (press release) “This decision could have a major impact for Quebec patients, since bendamustine combined with rituximab, is the only new treatment since the introduction of rituximab to have demonstrated a significant clinical improvement for patients living with an … |
|
BioInvent Extends Collaboration for the Discovery and Development of …
SelectScience.net (press release) BioInvent International AB today announces that it has signed an extension to its 2009 license agreement with Mitsubishi Tanabe Pharma Corporation for the development of antibodies from BioInvent’s n-CoDeR® library. Under the terms of the extension, … BioInvent extends license agreement with Mitsubishi TanabePharmaceutical Business Review |
|
Multiple Sklerose: Ein Anti-CD25-Antikörper verringert die Schubrate
Deutsches Ärzteblatt Daclizumab ist ein humanisierter monoklonaler Antikörper, der an CD25-Rezeptoren antagonistisch wirkt und immunologische Prozesse beeinflusst, die bei der multiplen Sklerose (MS) eine Rolle spielen. Bei einer Modifikation des Antikörpers (DAC HYP) … |
Obinutuzumab plus chlorambucil packs 1-2 punch against CLL in elderlyThe Oncology ReportIn the phase III CLL11 study, median progression-free survival (PFS) was 23 months for patients treated with a combination of obinutuzumab (GA101) and chlorambucil …